A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

NCT02882087 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of trial population, unable to recruit subjects

Conditions

Moderate and Severe Rheumatoid Arthritis

Interventions

DRUG: Placebo plus MTX
DRUG: RC18 160 mg plus MTX

Sponsor

RemeGen Co., Ltd.